CSIMarket
 
Centogene N v   (NASDAQ: CNTG)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 
Price: $0.3200 $-0.03 -8.571%
Day's High: $0.43 Week Perf: -4.48 %
Day's Low: $ 0.32 30 Day Perf: -28.9 %
Volume (M): 2,877 52 Wk High: $ 1.05
Volume (M$): $ 921 52 Wk Avg: $0.52
Open: $0.43 52 Wk Low: $0.25



 Market Capitalization (Millions $) 9
 Shares Outstanding (Millions) 28
 Employees 400
 Revenues (TTM) (Millions $) 54
 Net Income (TTM) (Millions $) -40
 Cash Flow (TTM) (Millions $) 40
 Capital Exp. (TTM) (Millions $) 0

Centogene N V
Centogene N V is a Netherlands-based company that operates in the genetic testing and diagnostics industry. The company specializes in the diagnostics of rare and genetic diseases as well as the provision of personalized medicine solutions. Centogene was founded in 2006 and has since then developed a unique approach to diagnosing rare diseases through its proprietary CentoMDe database.

The company's platform aims to provide a comprehensive understanding of the genetic basis of rare diseases, and they offer a wide range of diagnostic genetic testing services including targeted gene sequencing, whole-exome sequencing, whole-genome sequencing, and bioinformatics analysis. Their tests are performed using state-of-the-art technology and are designed to provide accurate and reliable results.

Centogene has developed a digitalized platform that connects the company's diagnostic services and proprietary database with the global medical community, providing an innovative ecosystem that enables physicians and researchers to collaborate easily and efficiently. As a result of this approach, Centogene has established partnerships with a wide range of stakeholders, including pharmaceutical and biotech companies, academic institutions, and patient organizations.

The company's mission is to improve the lives of patients by providing accurate diagnoses and personalized medicine solutions that can positively impact their treatment and disease management. To achieve this goal, Centogene N V invests heavily in research and development, collaborating with top academic institutions and pharmaceutical companies to innovate and improve its services.

Overall, Centogene N V is a leader in the genetic diagnostics industry, combining state-of-the-art technology with innovation and collaboration to improve patient care and disease management.


   Company Address: Am Strande 7 Rostock 18055
   Company Phone Number: 381 80113 500   Stock Exchange / Ticker: NASDAQ CNTG


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BNR        2.85% 
CDNA        5.55% 
DGX        1.75% 
EXAS   -7.26%    
GH        4.14% 
NTRA   -1.82%    
• View Complete Report
   



Clinical Study

CENTOGENE Publication in Brain Journal Reveals 15% of Parkinsons Disease Cases Are Linked to Genetic Factors

Published Thu, Aug 1 2024 8:16 PM UTC

Unlocking the Genetic Secrets of Neurodegenerative Diseases: CENTOGENE?s Breakthrough Studies on Parkinson s and Frontotemporal Dementia In an era where precision medicine is transforming the landscape of healthcare, the role of genetics in understanding and treating neurodegenerative diseases is becoming increasingly paramount. CENTOGENE N.V. (Nasdaq: CNTG), a leader in t...

Partnership

C-Path and CENTOGENE Collaborate in Advancing Research and Drug Development for Lysosomal Diseases

Published Thu, Jun 20 2024 12:01 PM UTC

Critical Path Institute (C-Path) and Centogene N.V. (CNTG) have recently signed a Memorandum of Understanding (MOU) to enhance collaboration in the field of lysosomal diseases (LDs). The partnership aims to accelerate drug development for LDs, a group of rare and neurodegenerative conditions, ultimately improving the quality of life for those affected.Details of the Collabor...

Financing Agreement

CENTOGENE Expands Relationship with Lifera and Secures $20 Million to Strengthen Cash Position

Published Wed, May 15 2024 9:10 PM UTC


recently reported on CENTOGENE s expanding relationship with Lifera, a biopharma company owned by the PIF. This news comes as CENTOGENE N.V. recorded a cumulative net loss of $-36 million during the 12 months ending in the fourth quarter of 2022.
Despite facing challenges in the Medical Laboratories industry, with employees of 14 other companies reaching higher in...

Product Service News

Promising New Molecule with Potential to Treat Gaucher Disease Discovered by CENTOGENE and Evotec

Published Tue, May 14 2024 12:31 PM UTC

Centogene N.V. (NASDAQ: CNTG), a pioneering figure offering data-driven solutions in rare and neurodegenerative diseases, in partnership with Evotec SE (Frankfurt Stock Exchange: EVT; MDAX/TecDAX; NASDAQ: EVO; ISIN: DE0005664809), made a groundbreaking announcement on May 14, 2024, from their respective headquarters in Cambridge, Massachusetts, Rostock, Germany, and Berlin. ...

Clinical Study

The CENTOGENE Biodatabank Bolsters Rare Disease Diagnosis: Unveiling Disease Insights From Over 850,000 Diverse Patients

Published Fri, May 10 2024 10:31 AM UTC

Centogene, a global leader in genetic diagnostics, has made groundbreaking strides in revolutionizing the diagnosis and understanding of rare and neurodegenerative diseases. With their biodatabank incorporating disease insights from over 850,000 diverse patients, Centogene has fueled the diagnosis of more than 2,500 rare and neurodegenerative diseases, published over 300 pee...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com